Skip to main content

Table 1 Characteristics of the population

From: Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Mean age (years±SD)

63.9 ± 13.4

Gender (male/female ratio)

8/4

Epistaxis (n/total)

12/12

ESS at enrolment (mean ± SD)

3.9 ± 2.8

Mucocutaneous teleangiectases other than endonasal (n/total)

11/12

Anemia in the 3 months before enrolment (n/total)

6/12

Mean Hb at enrolment (g/dl ± SD)

11.4 ± 2.9

Blood transfusion(s) in the 3 months before enrolment (n/total)

1/12

Family history of HHT (n/total)

11/12

Pulmonary AVMs (n/screened)

5/10

Hepatic AVMs (n/screened)

1/10

Cerebral AVMs (n/screened)

0/7

Gastrointestinal AVMs (n/screened)

5/7

Previous gastrointestinal bleeding (n/total)

5/12

Indication to AT

12/12

 Atrial Fibrillation (n/total)

4/12

 Venous thromboembolism (n/total)

1/12

 Previous stroke/transient ischemic attack (n/total)

5/12

 Previous myocardial infarction (n/total)

2/12

Number of AT courses / number of patients

 Anticoagulant therapy (n/total)

5/12

 Antiplatelet therapy (n/total)

7/12

Mean duration of follow-up (months ± SD)

6.5 ± 0.8

 Mean duration of antiplatelet therapy courses (months±SD)

6.9 ± 0.4

 Mean duration of anticoagulant therapy courses (months±SD)

6.2 ± 1.1